Sign in

    Michael Okunowicz • Maxim Group

    Michael Okunewitch is a Senior Research Analyst at Maxim Group with a focus on micro-cap and small-cap biotechnology and pharmaceutical companies. He provides coverage on firms such as Lexaria Bioscience, Radiopharm Theranostics, Anebulo Pharmaceuticals, Chemomab Therapeutics, and HCW Biologics, and has issued over 270 stock ratings since 2022. While his most profitable call generated a 350% return on Lexaria Bioscience, his overall success rate is approximately 34% with an average return per rating of -14%, ranking him in the lower percentiles among Wall Street analysts. Okunewitch began his analyst career at Maxim Group and currently holds the title of Senior Research Analyst; professional credentials are not publicly disclosed, but as a senior analyst at a FINRA-member firm, securities licenses are typically required.

    Michael Okunowicz's questions to Bionano Genomics Inc (BNGO) leadership

    Michael Okunowicz's questions to Bionano Genomics Inc (BNGO) leadership • Q2 2025

    Question

    Michael Okunowicz, on behalf of Jason McCarthy, inquired about the adoption rate of VIA software among OGM users, the strategy for marketing VIA to non-OGM users as a cross-selling opportunity, and the specific role of AI within the VIA software platform.

    Answer

    CEO Eric Holmlin explained that while VIA is installed in about a third of the total OGM base, the adoption rate is much higher among key 'routine use' customers, with significant opportunity still remaining. He confirmed that Bionano actively sells VIA for non-OGM applications like NGS and microarrays, viewing it as a 'Trojan horse' to introduce institutions to the Bionano ecosystem. Regarding AI, Dr. Holmlin described its function as accelerating and improving the analysis and categorization of genetic variants by computationally referencing various databases and publications.

    Ask Fintool Equity Research AI